Save this video free

Higher-Risk Myelodysplastic Syndromes | David Sallman, MD

Research To Practice · 42:33 · Watch on YouTube

These notes were made with YouTube Collector. Paste any YouTube link and get the same: a summary, chapters and a searchable transcript.

Overview

David Sallman describes how high-risk MDS treatment may improve by treating TP53-mutated disease as a distinct biological group, regardless of whether blasts fall on the MDS or AML side of an arbitrary cutoff. He reviews magrolimab plus azacitidine data, including responses, anemia precautions, transplant outcomes, and MRD findings, then discusses pivotal trials, sabatolimab, IDH inhibitors after HMA failure, and remaining treatment gaps.

Key takeaways

Chapters

0:00 TP53-Mutated MDS Case and the MDS-AML Treatment Overlap
6:34 Updated MDS Response Criteria and Early Clues to TP53 Mutation
12:43 Magrolimab’s CD47 Mechanism, Schedule, and Anemia Precautions
19:05 Magrolimab-Azacitidine Responses, Survival, Transplant, and MRD
24:14 TP53 AML Results, Phase 3 Trials, and Mutation Biology
31:56 Sabatolimab and TIM-3: Immune Checkpoint Promise and Trial Results
36:36 IDH Inhibitors After HMA Failure and Future High-Risk MDS Priorities
40:00 Clinical Q&A: IDH Inhibitor Durability and FLT3 in MDS

Keep these chapters and the full searchable transcript in your own library.

Transcript excerpt

0:00 hello my name is David Salman from mfet cancer center in Tampa Florida I'm an associate member in the myoid section head in the malignant hematology Department it's really a honor and pleasure to be here and look forward to all of our discussions you know my focus topic will be on future directions in the management of higher risk MDS and we'll really highlight uh several novel therapies as well as think about options that we may have after you know standard of care Frontline therapy and again look forward to these uh discussions so starting out with a case uh we have a 67-year-old male who presents with severe pancitopenia 12% myoblast um trilineage dysplasia and really part of the standard of care workup would be nection sequencing profile and notably it only showed one mutation but showed a p-53 mutation with a very high variant

0:48 alal frequency of 55% as well as Associated complex kype by cytogenetics this patient um is really otherwise fit minimal comorbidity still actually walking a mile per day at the time of presentation and really based on the store poor standard of care in this patient population we discussed clinical trial options and the patient was ultimately enrolled uh on a trial of as aedine with mamab the patient did have a two gram uh drop in the hemoglobin actually about four or five hours after the first infusion and had some notable increased you know symptomatic anemia this was transfused and actually subsequently really had no issues and no infusion related reactions this patient achieved uh marrow response or blast clearance with hologic Improvement and actually subsequently achieved a true complete

1:35 remission by iwg criteria and ultimately brid allergen a cell transplant and again I think this case both highlights an exciting new therapy as well as a

This is the start of the transcript. Save this video free for the whole transcript, searchable and time-coded.

Related notes

Summary, takeaways, and chapters were generated by AI from the video's transcript and may contain errors. The video belongs to its creator, Research To Practice.

Want the full transcript?

Save this video in YouTube Collector to get its complete searchable transcript, your own AI summaries, and a library that keeps every video you collect in one place.